Bilal Piperdi

VP, Clinical Research @Gileadsciences thoracic oncologist, clinical researcher, a proud Dad. Personal account and opinions, tweets and RT are my own opinion.

[Bilal Piperdi @bpiperdi]

It has been a bumpy year at personal level. As we head into #ASCO2023, thanks @GileadSciences for featuring my personal journey in Oncology. Special thanks to my Gilead team, all mentors/colleagues. We’re in this together to #endcancer #lcsm

[Gilead Sciences @GileadSciences]

Bilal Piperdi, Vice President of Clinical Research in Oncology, explains why he came to Gilead and how his Oncology team is helping to bring more life to people with lung cancer.

[Toni Choueiri, MD @DrChoueiri]

Two practice-informing trials at #ESMOBreast26 carry a broader lesson for oncology: sequencing #ADCs with the same payload class — here, a TOPO1 inhibitor — may not work simply by changing the target, linker, or PK.

BRE-354 from @ErikaHamilton9 @SarahCannonDocs and SATEEN from @PTarantinoMD @adawaksmd @DFCI_BreastOnc both speak to this important question.

This echoes what we have seen with PD-1 after PD-1 strategies: changing the partner drug does not necessarily overcome resistance to the same core mechanism. In RCC, two randomized phase III trials showed that this approach does not generally work:

TiNivo-2: https://t.co/AoYw8Q67U3
CONTACT-03: https://t.co/4VlJJalcC8

with @montypal @motzermd @AlbigesL @BradMcG04 in @TheLancet

The biology of resistance matters. Mechanism matters. Payload matters.

@myESMO @ASCO @AACR @OncoAlert

[Samuel Hume @DrSamuelBHume]

I was curious about the most cited (non-Covid) clinical trial from the last 10 years — it's this one: 11,288 citations

Pembrolizumab beat chemotherapy in PDL1–positive non–small-cell lung cancer, dislodged it as the first-line treatment (and ended up doubling median survival)

[FDA Oncology @FDAOncology]

#FDA approves a treatment for muscle invasive bladder cancer. https://t.co/ex0h3jLzwC

[ASCO @ASCO]

In 1991, US cancer death rates hit an all-time high. Advances in early detection & treatment helped bring mortality rates down, averting 4.5 million deaths.

Tell your lawmakers to support cancer research funding: https://t.co/ngriE8LS9N
#SaveResearchStopCancer #ASCOAdvocacy

[David Sirota @davidsirota]

The country’s highest profile Democratic politicians spent the day valorizing Dick Cheney while Democratic voters were busy electing Zohran Mamdani.

Let that sink in.

[Neal Augenstein @AugensteinWTOP]

60,000 white flags going up today on the National Mall, since November is Lung Cancer Awareness Month. Each flag represents two lives lost to #lungcancer. I'll share my story Wednesday at news conference, ahead of @LUNGevity's "Breathe Deep" event on Sat. Nov. 8 on the mall.

[Stephen V Liu, MD @StephenVLiu]

Review in JAMA on lung cancer in patients with no smoking history, who now make up about 20% of all new cases of lung cancer. The biology of these cancers is different, as is the treatment, but the gravity is the same. Read now at @JAMA_current.

https://t.co/zQhQh7AJSs

[NEJM @NEJM]

Presented at #ESMO25:

In untreated, advanced triple-negative breast cancer, sacituzumab govitecan led to significantly longer progression-free survival than chemotherapy (9.7 months vs. 6.9 months). Full ASCENT-03 phase 3 trial results: https://t.co/bqrtNPNct5

@myESMO

[Bilal Piperdi @bpiperdi]

2 NEJM and 1 Lancet simultaneous publication

[Bilal Piperdi @bpiperdi]

#ESMO25 Presidential symposium #2 3/4 potentially practiced changing/informing phase 3 trials conducted in China. What a change in landscape👏👏

[Bilal Piperdi @bpiperdi]

#ESMO25 Presidential symposium #2 3/4 potentially practiced changing/informing phase 3 trials conducted in China. What a change in landscape👏👏

[Bilal Piperdi @bpiperdi]

Finally something to improve over KN407 in 1L sq mNSCLC??? Eagerly awaiting OS results.. #ESMO25 #LCSM

[Tatiana Prowell, MD @tmprowell]

#ESMO25 Many phase 3 trials reporting out! Need a simple way to track FDA #OncTwitter approvals? Share & bookmark this page. It's an excellent resource for busy clinicians, everyone in #cancer #drugdevelopment, & Boards prep. Below is just 1 month! #regulatory #MedTwitter 1/2

[Excellence in Oncology Care - EIOC @EiocOncology]

👉Ascent 03 now out in #NEJM
👉Sacituzumab govitecan led to significantly longer progression-free survival than chemotherapy among patients with advanced triple-negative breast cancer who were not candidates for treatment with PD-1 or PD-L1 inhibitors.

#ESMO25 #ESMO2025 #NEJM

[Bilal Piperdi @bpiperdi]

Early morning walk in Barcelona for Presidential Symposium #WCLC2025

[Jill Feldman @jillfeldman4]

Congratulations @BrendonStilesMD @BalazsHalmosMD and @MontefioreNYC team on winning the @IASLC Care Team Award. It is well deserved!
#WCLC25 #LCSM

[Bilal Piperdi @bpiperdi]

@chulkimMD @LombardiCancer @StephenVLiu Congratulations 🎊🎈🎉

[Bilal Piperdi @bpiperdi]

Nice paper from France on Survival of Patients with Lung Adeno Dx. in 2000, 2010, and 2020 in a public hospitals. Huge impact of TKI and IO on survival! A lot more room to improve but importantly pts need access to these drugs globally!! ⁦@lcsmchat⁩ https://t.co/zPo6Yl8bm1

[Gilead Sciences @GileadSciences]

#GileadNews: In an open letter, Chairman and Chief Executive Officer Daniel O’Day discusses our just-approved #HIV prevention medication and its role in our fight to help end the epidemic: https://t.co/XcfwVra3fA

[American Board Certified Doctors for Egypt @doctor4egypt]

🚨 🚨 🚨 🚨 Big news for all future J-1 physicians!
Program Directors from all over the nation have received an Email from ECFMG telling them that
“the U.S. Department of State has lifted the pause on new visa appointments, and J-1 physicians have been explicitly prioritized for visa interview scheduling”!

Congratulations everyone!
"This is more than just an update—it’s a reminder that your dedication is paying off, and the doors to your future in U.S. medicine are wide open!"

#MedTwitter #IMG #j1visa

[Gilead Sciences @GileadSciences]

#GileadNews: The FDA has approved our injectable HIV-1 prevention medication, making it the first and only twice-yearly #HIV prevention option in the U.S. This approval is helping to usher in the future of prevention as we work to help end the epidemic. https://t.co/wGacaduPRn